Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

Attention-Deficit/Hyperactivity Disorder Clinical Trial

Official title:

A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01081132
• Other study ID #: SPD503-312
• Secondary ID: 2011-002221-21
• Status: Completed
• Phase: Phase 3
• Start date: September 19, 2011
• Est. completion date: May 16, 2013

Study information

• Verified date: June 2021
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the efficacy of optimized Extended-release Guanfacine Hydrochloride compared with placebo in the treatment of adolescents aged 13-17 years with a diagnosis of ADHD as measured by the ADHD-RS-IV

Recruitment information / eligibility

• Status: Completed
• Enrollment: 314
• Est. completion date: May 16, 2013
• Est. primary completion date: May 16, 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 13 Years to 17 Years

Eligibility

Inclusion Criteria:

1. Male or female, aged 13-17 years at the time of consent/assent (screening only).

2. Subject's parent or legally authorized representative (LAR) must provide signature of informed consent, and there must be documentation of assent by the subject indicating that the subject is aware of the investigational nature of the study and the required procedures and restrictions in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidance E6 (1996) and applicable regulations before completing any study-related procedures at screening.

3. Subject meets Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR) criteria for a primary diagnosis of ADHD, combined subtype, or hyperactive/impulsive subtype, based on a detailed psychiatric evaluation using the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime version (K SADS PL) at screening (re-confirm if baseline visit is >35 days from screening).

4. Subject has a minimum ADHD-RS-IV total score of 32 at baseline.

5. Subject has a minimum CGI-S score of 4 at baseline.

6. Subject is functioning at an age-appropriate level intellectually, as deemed by the Investigator.

7. Subject and parent/LAR understand, are able, willing and likely to fully comply with the study procedures and restrictions defined in this protocol.

8. Subject is able to swallow intact tablets.

9. All females must have a negative serum beta human Chorionic Gonadotropin (hCG) pregnancy test at screening and a negative urine pregnancy test at baseline. Female subjects must abstain from sexual activity that could result in pregnancy or agree to use acceptable methods of contraception.

10. Subject has a supine and standing blood pressure (BP) measurement within the 95th percentile for age, gender, and height.

Exclusion Criteria:

1. Subject has a current, controlled (requiring a prohibited medication or behavioral modification program) or uncontrolled, comorbid psychiatric diagnosis [except Oppositional Defiant Disorder (ODD), but including all anxiety disorders (except simple phobias)], all major depressive disorders (dysthymia allowed unless medication required), and any severe comorbid Axis II disorders or severe Axis I disorders such as post traumatic stress disorder, bipolar illness, psychosis, pervasive developmental disorder, obsessive-compulsive disorder, substance abuse disorder, or other symptomatic manifestations that, in the opinion of the Investigator, contraindicate SPD503 treatment or confound efficacy or safety assessments.

2. Subject has any condition or illness including clinically significant abnormal screening laboratory values which, in the opinion of the Investigator, represents an inappropriate risk to the subject and/or could confound the interpretation of the study.

3. Subject has a known history or presence of structural cardiac abnormalities, serious heart rhythm abnormalities, syncope, cardiac conduction problems (e.g., clinically significant heart block), exercise-related cardiac events including syncope and pre-syncope, or clinically significant bradycardia.

4. Subject has any abnormal or clinically significant ECG findings as judged by the Investigator with consideration of the central ECG interpretation.

5. Subject with orthostatic hypotension or a known history of controlled or uncontrolled hypertension.

6. Current use of any prohibited medication, including herbal supplements that affect blood pressure, heart rate, have central nervous system (CNS) effects, or affect cognitive performance, such as sedating antihistamines and decongestant sympathomimetics (inhaled bronchodilators are permitted) or a history of chronic use of sedating medications (i.e., antihistamines) at baseline.

7. Subject has a history of alcohol or other substance abuse or dependence, as defined by DSM IV-TR (with the exceptions of nicotine) within the last six months.

8. Subject has taken another investigational product within 30 days prior to baseline.

9. Subject is significantly overweight based on Center for Disease Control and Prevention Body Mass Index (BMI)-for-age gender specific charts at screening. Significantly overweight is defined as a BMI >95th percentile for this study.

10. Body weight of less than 34.0kg or greater than 91.0kg at screening.

11. Subject has a known or suspected allergy, hypersensitivity, or clinically significant intolerance to guanfacine hydrochloride or any components found in SPD503.

12. Clinically important abnormality on urine drug and/or alcohol screen (excluding the subject's current ADHD stimulant if applicable).

13. Subject is female and is pregnant or currently lactating.

14. Subject failed screening or was previously enrolled in this study.

15. Subject who is currently considered a suicide risk, has previously made a suicide attempt, or has a prior history of, or is currently demonstrating suicidal ideation.

16. History of failure to respond to an adequate trial (consisting of an appropriate dose and adequate duration of therapy), in the opinion of the Investigator, of an a2-agonist for the treatment of ADHD.

17. Subject has a history of a seizure disorder (other than a single childhood febrile seizure occurring before the age of 3 years) or a history of a tic disorder (including Tourette's syndrome).

Related Conditions & MeSH terms

• Attention Deficit Disorder with Hyperactivity
• Attention-Deficit/Hyperactivity Disorder
• Hyperkinesis

Intervention

Drug:
• Extended-release Guanfacine Hydrochloride
The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on weight.

Other:
• Placebo
Matching placebo will be provided as 1,2,3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on weight.

Locations

Country	Name	City	State
United States	Albuquerque Neuroscience Inc.	Albuquerque	New Mexico
United States	FutureSearch Trials	Austin	Texas
United States	Rainbow Research	Barnwell	South Carolina
United States	NorthCoast Clinical Trials	Beachwood	Ohio
United States	Northwest Clinical Research Center	Bellevue	Washington
United States	Florida Clinical Research Center, LLC	Bradenton	Florida
United States	IMMUNO International Research Centers	Centennial	Colorado
United States	The Ohio State University	Columbus	Ohio
United States	InSite Clinical Research	DeSoto	Texas
United States	Harmonex Neuroscience Research	Dothan	Alabama
United States	Triangle Neuropsychiatry	Durham	North Carolina
United States	Sarkis Clinical Trials	Gainesville	Florida
United States	Comprehensive Psychiatric Associates	Gladstone	Missouri
United States	Neuroscience, Inc.	Herndon	Virginia
United States	Amedica Research Institute, Inc.	Hialeah	Florida
United States	Goldpoint Clinical Research, LLC	Indianapolis	Indiana
United States	The Jackson Clinic	Jackson	Tennessee
United States	Clinical Neuroscience Solutions, Inc.	Jacksonville	Florida
United States	George M. Joseph, MD, PA	Jacksonville Beach	Florida
United States	East Side Therapeutic Resource	Kirkland	Washington
United States	R/D Clinical Research, Inc.	Lake Jackson	Texas
United States	Center for Psychiatry and Behavioral Medicine, Inc.	Las Vegas	Nevada
United States	Capstone Clinical Research	Libertyville	Illinois
United States	Clinical Study Centers, LLC	Little Rock	Arkansas
United States	Westex Clinical Investigations	Lubbock	Texas
United States	Clinical Neuroscience Solutions, Inc.	Memphis	Tennessee
United States	Research Strategies of Memphis, LLC	Memphis	Tennessee
United States	AMR-Baber Research Inc.	Naperville	Illinois
United States	Coastal Connecticut Research LLC	New London	Connecticut
United States	IPS Research Company	Oklahoma City	Oklahoma
United States	Clinical Neuroscience Solutions, Inc.	Orlando	Florida
United States	Morteza Nadjafi, MD, FAPA	Orlando	Florida
United States	Psychiatric Associates	Overland Park	Kansas
United States	Four Rivers Clinical Research, Inc.	Paducah	Kentucky
United States	CRI Worldwide	Philadelphia	Pennsylvania
United States	OCCI, Inc.	Portland	Oregon
United States	Alliance Research Group	Richmond	Virginia
United States	Finger Lakes Clinical Research	Rochester	New York
United States	Rochester Center for Behavioral Medicine	Rochester Hills	Michigan
United States	Peninsula Research Associates	Rolling Hills Estates	California
United States	Northwest Behavioral Research Center	Roswell	Georgia
United States	St Charles Psychiatric Associates - Midwest Research Group	Saint Charles	Missouri
United States	Oregon Center for Clinical Investigations, Inc.	Salem	Oregon
United States	Psychiatric Centers at San Diego (PCSD-Feighner Research Institute)	San Diego	California
United States	Institute for Behavioral Medicine	Smyrna	Georgia
United States	Miami Research Associates	South Miami	Florida
United States	Encompass Clinical Research	Spring Valley	California
United States	Richmond Behavioral Associates	Staten Island	New York
United States	Clinical Neurophysiology Services, PC	Sterling Heights	Michigan
United States	Clinco, Inc.	Terre Haute	Indiana
United States	Tulsa Clinical Research, LLC	Tulsa	Oklahoma
United States	University Services Sleep Diagnostic and Treatment Centers	West Chester	Pennsylvania
United States	Janus Center for Psychiatric Research	West Palm Beach	Florida
United States	Elite Clinical Trials, Inc.	Wildomar	California

Sponsors (1)

Lead Sponsor	Collaborator
Shire

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 13	The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.	Baseline through week 13
Secondary	Percent of Subjects With an Assessment of Normal/Borderline Mentally Ill on Clinical Global Impression-Severity of Illness (CGI-S) Scale at the Last On-Treatment Assessment	CGI-S assesses the severity of the subject's condition on a 7-point scale: 1 (normal, not at all ill), 2 (borderline mentally ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill), 7 (among the most extremely ill)	Baseline through week 13
Secondary	Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Learning and School Domain Scores at Week 13	The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). The Learning and School Domain consists of 10-items. Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.	Baseline and week 13
Secondary	Change From Baseline in the WFIRS-P Family Domain Score at Week 13	The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). The Family Domain consists of 10-items. Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.	Baseline and week 13
Secondary	Change From Baseline in the WFIRS-P Behavior in School Domain Score at Week 13	The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.	Baseline and week 13
Secondary	Change From Baseline in the WFIRS-P Global Domain Score at Week 13	The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.	Baseline and week 13
Secondary	Change From Baseline in the WFIRS-P Risk Domain Score at Week 13	The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). The Risk Domain consists of 10-items. Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.	Baseline and week 13
Secondary	Change From Baseline in the WFIRS-P Social Domain Score at Week 13	The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). The Social Domain consists of 7-items. Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.	Baseline and week 13
Secondary	Change From Baseline in the WFIRS-P Child Self-Concept Domain Score at Week 13	The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). The Child Self-Concept Domain consists of 3-items. Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.	Baseline and week 13
Secondary	Change From Baseline in the WFIRS-P Life Skills Domain Score at Week 13	The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). The Life Skills Domain consists of 10-items. Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.	Baseline and week 13
Secondary	Change From Baseline in the WFIRS-P Academic Performance Domain Score at Week 13	The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.	Baseline and week 13
Secondary	Percent of Subjects With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores at the Last On-Treatment Assessment	Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.	weeks 1 through 13
Secondary	Changes From Baseline in Behavior Rating Inventory of Executive Function (BRIEF) Scores at Week 13	Behavior Rating Inventory of Executive Function (BRIEF) is a questionnaire composed of three indices: Global Executive Composite, Behavioral Regulation Index, and Metacognition Index. Items are rated 1 (never), 2 (sometimes), and 3 (often). The Global Executive Composite consists of 72 items with scoring ranging from 72 to 216. The Behavioral Regulation Index score is the total of 28 items and ranges from 28 to 84. The Metacognition Index score is the total of 44 items and ranges from 44 to 132. Lower scores reflect better functioning.	Baseline and week 13
Secondary	Change From Baseline in Pediatric Daytime Sleepiness Scale (PDSS) Total Score at Week 13	The Pediatric Daytime Sleepiness Scale (PDSS) is an 8 item questionnaire scored on a scale from 0 (never) to 4 (always/very often). Total scores range from 0 to 32, with increasing score reflecting greater sleepiness.	Baseline through week 13
Secondary	Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Last On-Treatment Assessment	The BPRS-C characterizes childhood behavioral and emotional symptomatology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.	Baseline and week 13
Secondary	Structure Side-Effect Questionnaire (SSEQ)	The Structured Side-effect Questionnaire is a simple checklist of 17 side effects. The subject indicates whether a side effect has occurred since the last visit by marking 'yes' or 'no' on the checklist for each of the events listed.	Through week 16
Secondary	Columbia-Suicide Severity Rating Scale (C-SSRS)	C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.	Through week 16